Leukemia, Myelodysplasia, Transplantation
Video
Gilteritinib prolonged survival in FLT3-mutated AML
Patients with acute myeloid leukemia and FLT3-activating mutations are at increased risk for early relapse and poor overall survival.
News
Bendamustine/rituximab combo proves viable for comorbid CLL
Combination bendamustine and rituximab offers an effective treatment option for older, sicker patients with chronic lymphocytic leukemia.
News
Ibrutinib sustained responses in refractory CLL in long-term follow-up
Follow-up data from the RESONATE study suggests that long-term treatment with ibrutinib is effective and safe in patients with relapsed/refractory...
Conference Coverage
Anti-CD45 conditioning looks safe, feasible in relapsed AML
HOUSTON – Iomab-B use has resulted in successful engraftment for all patients who have received it and gone on to transplant, despite active...
Conference Coverage
Immunotherapy’s cardiac effects require early monitoring, management
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
News
Obinutuzumab-based regimens yield durable remissions in CLL
The findings suggest these new combinations may be more effective at clearing residual disease than rituximab-based therapy.
Conference Coverage
ALL chemotherapy looks effective in mixed phenotype leukemia
SAN DIEGO – In a retrospective cohort study, most children with mixed phenotype acute leukemia achieved MRD-negative complete response on ALL-...
Conference Coverage
Older CLL Patients See Better PFS With Ibrutinib
Ibrutinib, which is now widely used in older CLL patients, provided better progression-free survival than bendamustine and rituximab in a phase 3...
Conference Coverage
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...